Search Results - "Dimos, D"

Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies by Mitsikostas, Dimos D, Reuter, Uwe

“…The results of phase 2 randomized controlled trials for the prevention of episodic and chronic migraine demonstrating the efficacy and safety of four mAbs…”
Get full text

Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence by Mitsikostas, Dimos D., Rapoport, Alan

“…Treatment options for migraine have expanded rapidly over the past few years. The latest success in a phase II trial of a new class of drugs for migraine holds…”
Get full text

Rimegepant for migraine: acute efficacy beyond the USA by Mitsikostas, Dimos D

Get full text

Migraine: integrated approaches to clinical management and emerging treatments by Ashina, Messoud, Buse, Dawn C, Ashina, Håkan, Pozo-Rosich, Patricia, Peres, Mario F P, Lee, Mi Ji, Terwindt, Gisela M, Halker Singh, Rashmi, Tassorelli, Cristina, Do, Thien Phu, Mitsikostas, Dimos D, Dodick, David W

“…Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ…”
Get full text

Effect of Cap Management Frequency on the Phenolic, Chromatic, and Sensory Composition of Cabernet Sauvignon Wines from the Central Coast of California over Two Vintages by Casassa, L Federico, LoMonaco, Isabelle, Velasco, Marcel, Papageorgas, Dimos D

“…Cabernet Sauvignon from the California Paso Robles AVA was processed with a contrasting array of cap management frequencies, consisting of punch-down (PD)…”
Get full text

Nocebos in rheumatology: emerging concepts and their implications for clinical practice by Kravvariti, Evrydiki, Kitas, George D., Mitsikostas, Dimos D., Sfikakis, Petros P.

“…Nocebo effects are noxious reactions to therapeutic interventions that occur because of negative expectations of the patient. In the past decade,…”
Get full text

Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies by Stanulović, Vid, Hodolic, Marina, Mitsikostas, Dimos D., Papadopoulos, Dimitrios

“…Aims Drug tolerability refers to the degree to which drugs' overt adverse effects can be tolerated by patients. The tolerability profile is of comparative…”
Get full text

Monoclonal Antibodies as Neurological Therapeutics by Gklinos, Panagiotis, Papadopoulou, Miranta, Stanulovic, Vid, Mitsikostas, Dimos D, Papadopoulos, Dimitrios

“…Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties,…”
Get full text

Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number? by Barbanti, Piero, Egeo, Gabriella, Mitsikostas, Dimos D.

“…Trigeminal‐targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients…”
Get full text

Nocebo in clinical trials for depression: A meta-analysis by Mitsikostas, Dimos D, Mantonakis, Leonidas, Chalarakis, Nikolaos

“…Abstract Nocebo refers to adverse events (AEs) related to negative expectations that medical treatment will likely harm instead of heal and can be assessed in…”
Get full text

Nocebo in headache by Mitsikostas, Dimos D

“…This article addresses nocebo in headache. Nocebo is the antipode of placebo and refers to adverse events a person manifests after receiving placebo. In…”
Get full text

Male and female sex hormones in primary headaches by Delaruelle, Zoë, Ivanova, Tatiana A., Khan, Sabrina, Negro, Andrea, Ornello, Raffaele, Raffaelli, Bianca, Terrin, Alberto, Mitsikostas, Dimos D., Reuter, Uwe

“…Background The three primary headaches, tension-type headache, migraine and cluster headache, occur in both genders, but all seem to have a sex-specific…”
Get full text

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials by Gklinos, Panagiotis, Mitsikostas, Dimos D.

“…Background: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest…”
Get full text

Diagnosis and management of migraine in ten steps by Eigenbrodt, Anna K., Ashina, Håkan, Khan, Sabrina, Diener, Hans-Christoph, Mitsikostas, Dimos D., Sinclair, Alexandra J., Pozo-Rosich, Patricia, Martelletti, Paolo, Ducros, Anne, Lantéri-Minet, Michel, Braschinsky, Mark, del Rio, Margarita Sanchez, Daniel, Oved, Özge, Aynur, Mammadbayli, Ayten, Arons, Mihails, Skorobogatykh, Kirill, Romanenko, Vladimir, Terwindt, Gisela M., Paemeleire, Koen, Sacco, Simona, Reuter, Uwe, Lampl, Christian, Schytz, Henrik W., Katsarava, Zaza, Steiner, Timothy J., Ashina, Messoud

“…Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine…”
Get full text

Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review by Amanzio, Martina, Mitsikostas, Dimos D, Giovannelli, Fabio, Bartoli, Massimo, Cipriani, Giuseppina Elena, Brown, Walter A

“…For safety assessment in clinical trials, adverse events (AEs) are reported for the drug under evaluation and compared with AEs in the placebo group. Little is…”
Get full text

Aging, Cellular Senescence, and Progressive Multiple Sclerosis by Papadopoulos, Dimitrios, Magliozzi, Roberta, Mitsikostas, Dimos D., Gorgoulis, Vassilis G., Nicholas, Richard S.

“…Ageing is one of the most important risk factors for the development of several neurodegenerative diseases including progressive multiple sclerosis (MS)…”
Get full text

Therapies targeting CGRP signaling for medication overuse headache by Koumprentziotis, Ioannis-Alexios, Mitsikostas, Dimos D.

“…Medication overuse headache (MOH) affects more than 60 million individuals worldwide causing enormous personal and social burden. Only repurposed drugs are…”
Get full text

Making headway — a role for CGRP in post-traumatic headache by Mitsikostas, Dimos D., Moskowitz, Michael A.

“…Although common, post-traumatic headache remains poorly understood and poorly treated. New data have implicated calcitonin gene-related peptide and the…”
Get full text

Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review by Mitsikostas, Dimos‐Dimtirios D., Caronna, Edoardo, De Tommaso, Marina, Deligianni, Christina I., Ekizoglu, Esme, Bolay, Hayrunnisa, Göbel, Carl H., Kristoffersen, Espen Saxhaug, Lampl, Christian, Moro, Elena, Pozo‐Rosich, Patricia, Sellner, Johann, Terwindt, Gisela, Irimia‐Sieira, Pablo

“…Background and purpose The aim was to provide insights to the characteristics of headache in the context of COVID‐19 on behalf of the Headache Scientific Panel…”
Get full text

Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis by Kokoti, Lili, Drellia, Konstantina, Papadopoulos, Dimitrios, Mitsikostas, Dimos D.

“…High placebo and low nocebo phenomena mirror high positive expectations for a novel treatment, among other reasons. In a meta-analysis aimed to identify…”
Get full text